Trastuzumab Active Not Recruiting Phase 2 Trials for Stage II Breast Cancer / Her2-Positive Breast Cancer / Recurrent Breast Cancer / Stage IA Breast Cancer / HER2-Negative Breast Cancer / Stage IIIC Breast Cancer / Stage IIIB Breast Cancer / Stage IB Breast Cancer / Stage IIIA Breast Cancer / Cancer, Breast Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01796197Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
NCT00295893Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
NCT00003612Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT02073487Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
NCT01491737A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
NCT00971737Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00254592Neoadjuvant Treatment of Breast Cancer
NCT00470704Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
NCT01625429Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
NCT00796978Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
NCT01853748T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
NCT02132949A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT00618657Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
NCT00820872Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
NCT00999804Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
NCT01855828Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
NCT01745965A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.